Anti-CD20 monoclonal antibodies: reviewing a revolution

Casan, Joshua; Wong, Jonathan; Northcott, Melissa; Opat, Stephen

doi:10.1080/21645515.2018.1508624

Cited by 81 publications

(76 citation statements)

References 252 publications

(239 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 a Natural killer- (NK-) cells (CD56 bright CD16 + ) and T helper -cell subsets in rituximab (RTX) treated MS vs. RRMS without RTX, and healthy controls [4]. b Regulatory T-cells (CD4 + CD25 + FoxP3 + ), c Th1-cells (CD4 + IFNγ + ) …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

et al. 2018

View full text Add to dashboard Cite

BackgroundWith ocrelizumab another drug is available for the treatment of multiple sclerosis (MS). Little is known on the long-term use of ocrelizumab on immune cell subsets, and no surrogate markers are available. Rituximab (RTX) has been in off-label use for the treatment of MS, neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD) for > 10 years.ObjectiveWe evaluated the long-term depletion and repopulation rate of peripheral CD19+ B-cells as a potential surrogate for the clinical outcome, and whether it may serve for dosage and time-to-infusion decision making.MethodsWe evaluated the CD19+ and CD4+/8+ T-cell counts in n = 153 patients treated with RTX (132 MS, 21 NMO/NMOSD). The dosages ranged from 250 to 2000 mg RTX. Depletion/repopulation rates of CD19+ B-cells as well as long-term total lymphocyte cell counts, were assessed and corroborated with EDSS, ARR (annualized relapse rate), MRI, and time to reinfusion.ResultsCD19+ B-cells’ repopulation rate significantly varied depending on the dosage applied leading to individualized application intervals (mean 9.73 ± 0.528 months). Low/absent CD19+ B-cell counts were associated with reduced ARR, EDSS, and GD+-MRI-lesions. Long-term B-cell-depleting therapy led to a transiently skewed CD4+/8+ T-cell ratio due to reduced CD4+ T-cells and absolute lymphocyte counts, which recovered after the second cycle.ConclusionOur data suggest that CD19+ B-cell repopulation latency may serve as surrogate marker for individualized treatment strategies in MS and NMO/NMOSD, which proved clinically equally effective in our cohort as evaluated by previous studies.

show abstract

Section: Resultsmentioning

confidence: 99%

“…There is growing evidence for the efficacy of B-cell depleting therapies in various autoimmune diseases [ 4 ]. This has previously resulted in the FDA approval of RTX for the treatment of rheumatoid arthritis in 2006.…”

Section: Discussionmentioning

confidence: 99%

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Table 3 shows examples of therapeutic Abs for treating human diseases. Therapeutic Abs have had enormous success, exemplified by Rituximab (an anti-CD20 MAb), which is the first therapeutic MAb for treating lymphoma and used for treatment of several autoimmune diseases [112]. Other notable examples are recombinant MAbs to tumour necrosis factor, TNF, and programmed death-1, PD-1, used for treating rheumatoid arthritis and malignant melanoma, respectively [74,75].…”

Section: Recombinant Antibodiesmentioning

confidence: 99%

Peptides, Antibodies, Peptide Antibodies and More

Trier

Hansen

Houen

2019

IJMS

View full text Add to dashboard Cite

The applications of peptides and antibodies to multiple targets have emerged as powerful tools in research, diagnostics, vaccine development, and therapeutics. Antibodies are unique since they, in theory, can be directed to any desired target, which illustrates their versatile nature and broad spectrum of use as illustrated by numerous applications of peptide antibodies. In recent years, due to the inherent limitations such as size and physical properties of antibodies, it has been attempted to generate new molecular compounds with equally high specificity and affinity, albeit with relatively low success. Based on this, peptides, antibodies, and peptide antibodies have established their importance and remain crucial reagents in molecular biology.

show abstract

“…122 This drug was initially used to treat lymphomas but currently is being used for the treatment of certain autoimmune diseases. 123 The effect of rituximab results from its regulatory effect on the cell cycle, including apoptosis stimulation, complement-dependent B cell lysis, and antibody-dependent cell-mediated cytotoxicity. 124 Recent studies showed that rituximab not only affects B cells but has another possible mechanism of action against CD20 + T cells in MS patients, 125 or in EAE mice.…”

Section: Rituximab Effects On the Chemokines And Chemokine Receptorsmentioning

confidence: 99%

<p>Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis</p>

Dhaiban

Al‐Ani

Elemam

et al. 2020

JIR

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an immune-mediated and neurodegenerative disorder that results in inflammation and demyelination of the central nervous system (CNS). MS symptoms include walking difficulties, visual weakening, as well as learning and memory impairment, thus affecting the quality of the patient's life. Chemokines and chemokine receptors are expressed on the immune cells as well as the CNS resident cells. Several sets of chemokine receptors and their ligands tend to be pathogenic players in MS, including CCL2,

show abstract

Anti-CD20 monoclonal antibodies: reviewing a revolution

Cited by 81 publications

References 252 publications

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders

Peptides, Antibodies, Peptide Antibodies and More

<p>Targeting Chemokines and Chemokine Receptors in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis</p>

Contact Info

Product

Resources

About